Eric M. Kraus – Phillips Lytle LLP

Eric is co-chair of Phillips Lytle’s Life Sciences and Health Effects Team and a member of the firm’s Psychedelics and Mental Health Therapeutics Team.

He has represented some of the largest international pharmaceutical companies in various life science matters across the U.S. He has defended cases centered on cutting-edge scientific and medical issues, with an emphasis on developing and presenting expert witness testimony and opposing expert witnesses proffered by adverse parties. He is also an experienced trial lawyer who has tried more than 40 cases to verdict in state and federal courts and has argued appeals in all levels of appellate courts in New York State, including in the New York State Court of Appeals and U.S. Court of Appeals for the Second Circuit.

Eric has published articles and spoken on topics dealing with scientific issues, expert testimony and innovative legal issues. He has co-authored several related to psychedelics such as the FDA Guidance on clinical trials for psychedelics and the APA’s Position Paper on psychedelic use.

Publications

• Insights for Psychedelic Stakeholders From Recent FDA Public Meeting on Advancing Treatments for PTSD
• FDA Denies Approval of New Drug Application for MDMA and Requests Additional Study
• Federal Agencies Discuss Steps to Advance PTSD Treatments, Including Psychedelics
• A Recent FDA-Sponsored Meeting Addressed Psychedelic Drug Development, Including the Limits of FDA’s Regulatory Authority
• FDA Breakthrough Therapy Designation for LSD Formulation
• Progress for Research Funding on Psychedelics for Military Personnel and Veterans/First Responders
• APA Issues Position Statement on Psychedelics Use
• FDA Draft Guidance on Clinical Trials for Psychedelics